DeepCure’s Post

Great piece in The Irish Times with Sinead Keogh at BioPharmaChem Ireland, highlighting the importance of continued support for industry-academic collaborations; attracting and retaining international pharma and biopharma companies and talent. SSPC is working on strengthening Ireland's position as a global leader in advanced #medicine #research, ensuring Ireland remains at the forefront, creating high-value jobs, driving growth and attracting future investment. 📌SSPC supports over 2,400 Irish jobs, employing over 394 highly skilled professionals. 📌SSPC has supported >300 alumni for the (bio)pharma sector. This #talent pipeline is critical for growth, while future proofing the sector in Ireland. Research Ireland

REGISTRATION IS OPEN! SIGN UP FOR FREE NOW! https://lnkd.in/eBtwsuNA At ELRIG we have no membership costs, or events fees - just brilliant science, incredible exhibitors and engaged delegates! Join us in Gothenburg 14-15 May for Therapeutic OLIGOS 2025! The second ELRIG meeting on Therapeutic Oligonucleotides, will be hosted at the AstraZeneca R&D site in Gothenburg. This dynamic event aims to build upon the success of the inaugural Therapeutic Oligonucleotides meeting and the well-regarded Advances in Cell-Based Assays in Drug Discovery. Esteemed scientists from academia, industry, and the vendor community will convene to explore the discovery, validation, and targeting of drug candidates using antisense oligonucleotides (ASOs) and siRNA. Our ambition is to establish an open-access meeting that fosters an inspiring environment for networking, encouraging collaboration between biologists and chemists across diverse research areas.   Oligonucleotide-based drugs, including ASOs and siRNAs, are already significantly impacting patients’ lives. The conference will delve into the nature of drug targets amenable to modulation by oligonucleotides, while comparing the advantages and limitations of these modalities with other drug types. Recent advancements in broadening their application, including innovative approaches to ensure their safety and efficacy, as well as the use of targeted delivery to reach disease-relevant tissues, will be covered. Success stories in bringing therapeutic oligonucleotides to the clinic will also be shared. The scientific sessions over two days will cover the following key areas detailed in the track information below. Conference Directors: Fredrik Edfeldt David Gilot Linda Sundström Karl-Johan Leuchowius Ulrik Lytt Rahbek Pär Matsson Saman Honarnejad #ELRIG #ELRIGTO2025 #TO2025

This is an excellent article with strong contributions by Sinead Keogh (BPCI), Finnian Müller Hanrahan (Research Ireland) and Derek Collins (Huawei). As we near the end of 2024 and with government formation talks ongoing, they make a valid argument for increased focus and investment in research that supports and strengthen collaborations between Irish academia and the biopharma/biotech industry. To fulfil its ambitions as a global biopharma and life science leader, Ireland needs a renewed state focus and increased investment.

Let’s connect

‘Ireland has an enviable position in the life sciences industry, with nine of the top 10 pharmaceutical companies in the world based here. The State is the world’s third-largest exporter of pharmaceuticals, shipping more than €80 billion a year in exports, according to the IDA.’

I am speaking Wednesday, Apr 17 at 11:40 AM EST in the Pharmaceutical R&D Informatics program at Bio-IT World Conference & Expo. The Evolution of PiG Disco: From the Centralization of HLA Peptide in Groove Data through the Advancements of New Enhancements for Quicker Target Discovery/Validation Deciphering the composition of the human immunopeptidome is important to understand the immune system and to guide in the development of next-generation vaccines and immunotherapies against autoimmunity, infectious diseases, and cancers. Mass spectrometry is the only available technology to interrogate the immunopeptidome in an accurate manner, yet we had only had a rudimentary way of searching through all this data. Follow our journey in how we implemented a powerhouse application. https://lnkd.in/ephT7Bc4

There’s only 1 week remaining until our free advanced #ADME symposium + personalized workshop in Brussels, so reserve your spot today! Join us on April 11 for a tour of BioIVT’s lab in Belgium and hear experts present a variety of research topics and case studies. Then on April 12, attend a workshop to see product demonstrations and talk to experts about applications in your research. You can register to attend one or both dates: https://lnkd.in/e7eQTwB7 April 11 Presentations: - Carboxylesterases in Drug Metabolism: Challenges and Opportunities - A Human 3D Liver-Chip Model Composed of Primary Human Hepatocytes for Drug Safety and ADME Predictions - siRNA Delivery in a Long-Term Hepatic Micropatterned Co-Culture (HEPATOPAC): Methods and Applications - Understanding How a Transporter Allows an Acetylated Amino Acid to Act as a Drug - Drug-Drug Preclinical Interactions Studies: Merck Examples Spotting Importance of Design and Test Article Properties - Development of Antibody-Drug Conjugates: Safety and ADME Considerations April 12 workstations include #HEPATOPAC®️, cryoplated #hepatocytes, #BACTOSOMES®️ recombinant #enzymes, fresh tissue and more. Learn more and register: https://lnkd.in/e7eQTwB7 #druginteractions #drugtransporters #drugmetabolism #DMPK

University of Tartu is participating in the European cancer study consortium OPTIMA 🇪🇺🧬🥼 One of the many goals of OPTIMA is to produce a clinical decision support tool to assist clinicians in making evidence-based decisions for medical interventions of different types of cancer. This week, me together with Mart Kals, research fellow in statistical genomics, and Raivo Kolde, associate professor of health informatics, are representing Estonia 🇪🇪 in the OPTIMA prototyping workshop in Berlin, Germany. 🇩🇪 The three of us are currently formulating prostate cancer risk calculation. Together with many collaborators and leaders in different fields of research, we will be looking into how to apply it in a real-world setting. #europe #cancer #OPTIMA #oncology #healthcare

🌟 Only 15 Days Left Until the Sino Biological Symposium on Immuno-Oncology! 🌟 We're thrilled to invite you to the Sino Biological Symposium, a pivotal gathering that highlights monumental advancements in the realm of Immuno-oncology. This event will focus on cutting-edge antibody engineering and the transformative journey of drug discovery from inception to commercialization. 🔬Why Attend?🔬 Engage with a distinguished panel of industry leaders from #Anaveon_AG, #Curio_Biotech, #University_of_Basel, #GIO_Therapeutics, and #Sino_Biological Dive deep into discussions about the role of innovative technology in enhancing drug development processes, accelerating scientific breakthroughs, and ensuring therapeutic safety. Foster rich dialogue, exchange knowledge, and catalyze partnerships that push the boundaries of healthcare innovation. 🌐 Event Details: #Date: Thursday, 16th of May 2024 #Venue: Novartis Pavillon, Basel, Switzerland #Organized by: Sino Biological Europe GmbH 👥 Who Should Attend?👥 If you're a professional in the biotech, pharmaceutical, healthcare, or academic sectors, or simply interested in the future of healthcare innovations, this symposium is for you! Secure your spot now and be part of shaping the future of Immuno-oncology. Let’s pave the way for new collaborations and advancements within the life sciences sector. 🔗🔗🔗 Click here to register and learn more: https://lnkd.in/eZVTKpcK We can't wait to see you there! #SinoBiological #ImmunoOncology #DrugDiscovery #AntibodyEngineering #HealthcareInnovation #BiotechEvent #PharmaIndustry #LifeSciences

Executive Summary of BIO-Europe 2024 Stockholm, November 6, 2024 – BIO-Europe 2024, organized by EBD Group, has once again demonstrated its pivotal role in the life sciences sector, bringing together over 5,000 industry leaders, investors, and innovators from across the globe. Held in Stockholm, this year’s event provided a platform for breakthrough insights and transformative discussions in biotechnology, pharmaceutical advancements, and the future of precision medicine. Carl Michael Bergman, CEO of Opticom, shared his vision for the evolving landscape of drug development, particularly highlighting the critical role of data-driven decision-making in advancing patient care. Through strategic interviews, including an in-depth session with Mavatar’s CEO, he underscored the importance of collaboration between biotech companies, diagnostics, and digital health solutions to enhance targeted therapies and bring precision medicine to the forefront. Key takeaways from the conference: • Innovation in Precision Medicine: A strong focus on advancements in diagnostics and patient stratification to personalize treatments, with data utilization as a cornerstone. • Investor-Driven Partnerships: Increased investor interest in collaborative models, especially those bridging pharmaceutical and biotech sectors with diagnostic companies, was evident throughout discussions and partnership meetings. • Europe as a Hub for Life Sciences: Stockholm’s hosting of BIO-Europe underscored Europe’s strategic role in life sciences innovation, providing a vibrant ground for collaboration and investment opportunities. Looking forward, Opticom Group is excited to continue engaging with industry stakeholders to foster partnerships that accelerate the adoption of precision medicine globally. We believe that through collaboration and innovation, we can drive better decisions and outcomes in healthcare. For further information, send linked in mail or visit Mavatar Thanks EBD Group, Business Sweden SwedenBIO Lif - de forskande läkemedelsföretagen STUNS Life science Stockholm Science City Karolinska Institutet Vinnova BioArctic Sobi - Swedish Orphan Biovitrum AB (publ) Calliditas Therapeutics Isofol Medical AB (publ) Ulrika Nyberg Björn Arvidsson Britta Stenson, PhD 🤩👏🙏❤️